Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Nashan

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Transplantation Proceedings|December 26, 2001
The IL2 pathway in clinical immunosuppressionB Nashan
Transplantation Proceedings|December 26, 2001
The role of Certican (everolimus, rad) in the many pathways of chronic rejectionB Nashan
Transplantation Proceedings|January 5, 2000
The interleukin-2 inhibitors and their role in low-toxicity regimensB Nashan
Transplant Immunology|January 19, 2000
Expression patterns of integrin receptors and extracellular matrix proteins in chronic rejection of human liver allograftsG Demirci, K Hoshino, B Nashan
Transplantation|December 27, 1996
Fibrosis in chronic rejection of human liver allografts: expression patterns of transforming growth factor-TGFbeta1 and TGF-beta3G Demirci, B Nashan, R Pichlmayr
Transplantation Proceedings|September 2, 1998
Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study GroupsF Vincenti, B Nashan, S Light
British Journal of Anaesthesia|November 1, 1984
Droperidol inhibits cardiac vagal efferents in dogsB Nashan, K Inoue, J O Arndt
European Journal of Pharmacology|April 2, 1985
[D-Met2,Pro5]enkephalinamide activates cardioinhibitory efferents in anaesthetized dogsK Inoue, B Nashan, J O Arndt
Transplantation Proceedings|October 1, 1987
Selective increase of CD8+ CD11+ cells in long-term liver allograft recipientsR Schwinzer, K Wonigeit, B Nashan, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|January 1, 1994
Expression of cell-matrix molecules and integrin receptors in human liver grafts during chronic rejectionK Hoshino, B Nashan, G Steinhoff, et al.
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Transplantation Proceedings|December 26, 2001
The IL2 pathway in clinical immunosuppressionB Nashan
Transplantation Proceedings|December 26, 2001
The role of Certican (everolimus, rad) in the many pathways of chronic rejectionB Nashan
Transplantation Proceedings|January 5, 2000
The interleukin-2 inhibitors and their role in low-toxicity regimensB Nashan
Transplant Immunology|January 19, 2000
Expression patterns of integrin receptors and extracellular matrix proteins in chronic rejection of human liver allograftsG Demirci, K Hoshino, B Nashan
Transplantation|December 27, 1996
Fibrosis in chronic rejection of human liver allografts: expression patterns of transforming growth factor-TGFbeta1 and TGF-beta3G Demirci, B Nashan, R Pichlmayr
Transplantation Proceedings|September 2, 1998
Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study GroupsF Vincenti, B Nashan, S Light
British Journal of Anaesthesia|November 1, 1984
Droperidol inhibits cardiac vagal efferents in dogsB Nashan, K Inoue, J O Arndt
European Journal of Pharmacology|April 2, 1985
[D-Met2,Pro5]enkephalinamide activates cardioinhibitory efferents in anaesthetized dogsK Inoue, B Nashan, J O Arndt
Transplantation Proceedings|October 1, 1987
Selective increase of CD8+ CD11+ cells in long-term liver allograft recipientsR Schwinzer, K Wonigeit, B Nashan, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|January 1, 1994
Expression of cell-matrix molecules and integrin receptors in human liver grafts during chronic rejectionK Hoshino, B Nashan, G Steinhoff, et al.
Pageof 13